ANHEART THERAPEUTICS

AnHeart Therapeutics Announces Presentation at the European Lung Cancer Congress (ELCC) 2022

Retrieved on: 
Monday, March 21, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Company, Cancer, Therapy, Pemetrexed, Crizotinib, EML4-ALK positive lung cancer, Entrectinib, Traffic barrier, Clinical trial, RECIST, ORR, TKI, University of California, School, University of California, Irvine, Program, Colorectal cancer, Platinum, Medical school, AXL, NSCLC, Poster, Korea, CEO, PFS, Safety, IRC, ROS1, UC, Lung cancer, University, Patient, Lung, Pharmaceutical industry, Glioblastoma, Cholangiocarcinoma, TRUST-II STUDY, TALETRECTINIB, ANHEART THERAPEUTICS, TRUST-II STUDY, TALETRECTINIB, ANHEART THERAPEUTICS

AnHeart Therapeutics (AnHeart), a clinical-stage global biopharmaceutical company committed to developing novel precision oncology therapeutics, today announced a poster presentation for ROS1 inhibitor taletrectinib at the European Lung Cancer Congress 2022, held in Prague, Czech Republic, and virtually, March 30-April 2, 2022.

Key Points: 
  • AnHeart Therapeutics (AnHeart), a clinical-stage global biopharmaceutical company committed to developing novel precision oncology therapeutics, today announced a poster presentation for ROS1 inhibitor taletrectinib at the European Lung Cancer Congress 2022, held in Prague, Czech Republic, and virtually, March 30-April 2, 2022.
  • Details of the poster presentation are below:
    Poster Presentation Title: TRUST-II: A Global Phase II Study for Taletrectinib in ROS1 fusion Positive Lung Cancer and other solid tumors.
  • Date/Time: The e-Posters will be available on the virtual platform of the ELCC website, in the e-Posters section, as of 29 March at 12:00 CEST.
  • AnHeart Therapeutics (AnHeart), a Cayman Islands entity (registered name AnBio Therapeutics Ltd.), is a clinical-stage global biopharmaceutical group company developing a broad pipeline of novel or next-generation precision oncology therapeutics with high unmet medical needs.

AnHeart Therapeutics and Innovent Biologics Receive NMPA Breakthrough Designation for Taletrectinib in ROS1 Fusion-Positive Non-Small Cell Lung Cancer

Retrieved on: 
Tuesday, March 1, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, MD Anderson Cancer Center, Social conditions in Honduras, Crizotinib, CSCO, Annual general meeting, Therapy, BTD, HKEX, Company, CMC, AXL, Senior, Lung cancer, Stock exchange, ALT, Hereditary nonpolyposis colorectal cancer, Environment, Safety, Chinese, NMPA, Review, Center for Drug Evaluation and Research, Autoimmunity, Lung, NSCLC, Entrepreneurship, AST, Metabolism, Breakthrough therapy, CDE, Bevacizumab, DCR, Center, Trial of the century, Cancer, Eli Lilly and Company, ROS1, ORR, Integrity, Patient, Control, TKI, Clinical trial, Motherboard, Nature, News, Chemistry, Marketing, Large-cell lung carcinoma, MD, Pharmaceutical industry, Incyte, Glioblastoma, Cholangiocarcinoma, Center for Innovative Phage Applications and Therapeutics, Taletrectinib, AnHeart Therapeutics, Innovent, TALETRECTINIB, ANHEART THERAPEUTICS, INNOVENT

The NMPA Breakthrough Therapy Designation was based on results from the Phase 2 TRUST trial of ROS1 fusion-positive NSCLC patients treated with taletrectinib, a new generation of potent ROS1 inhibitors.

Key Points: 
  • The NMPA Breakthrough Therapy Designation was based on results from the Phase 2 TRUST trial of ROS1 fusion-positive NSCLC patients treated with taletrectinib, a new generation of potent ROS1 inhibitors.
  • "There is a high unmet medical need for lung cancer patients with ROS1 fusion mutations," said Bing Yan, MD, Co-Founder and Chief Medical Officer at AnHeart Therapeutics.
  • We are glad to see the NMPA grant Breakthrough Therapy Designation based on the Phase 2 data of taletrectinib, said Dr. Hui Zhou, Senior Vice President of Innovent.
  • Taletrectinib is a novel best-in-class next-generation ROS1 inhibitor designed to effectively target ROS1 fusion mutations with potential to treat both TKI-nave and pre-treated patients.

AnHeart Therapeutics Announces First Patient Dosed in Global Phase 2 TRUST-II Study for Taletrectinib in ROS1 Fusion-Positive Lung Cancer

Retrieved on: 
Monday, October 25, 2021
Oncology, Health, FDA, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Safety, MD, TRUST, Entrepreneurship, AXL, CSCO, Neoplasm, History, Patient, Lung, Large-cell lung carcinoma, Ovarian cancer, ORR, TKI, Company, Cholangiocarcinoma, Clinical trial, Breast, AML, ROS1, Therapy, ASCO, Pharmaceutical industry, Taletrectinib, AnHeart Therapeutics, TALETRECTINIB, ANHEART THERAPEUTICS

AnHeart Therapeutics (AnHeart), a clinical-stage global biopharmaceutical company committed to developing novel cancer therapies, today announced that the first patient has been dosed in the global Phase 2 trial of taletrectinib in ROS1 fusion-positive lung cancer (TRUST-II).

Key Points: 
  • AnHeart Therapeutics (AnHeart), a clinical-stage global biopharmaceutical company committed to developing novel cancer therapies, today announced that the first patient has been dosed in the global Phase 2 trial of taletrectinib in ROS1 fusion-positive lung cancer (TRUST-II).
  • By targeting ROS1, taletrectinib is designed to deliver cancer-fighting therapeutics selectively to tumor cells, while sparing normal cells.
  • Taletrectinib dosing of the first patient in our global Phase 2 ROS1 fusion-positive TRUST-II lung cancer trial represents a key milestone for our lead ROS1-directed clinical program, said Bing Yan, MD, Co-Founder and Chief Medical Officer of AnHeart Therapeutics.
  • The global Phase 2 study (TRUST-II) is a multicenter, single-arm, open label study of taletrectinib in patients of NSCLC harboring with ROS1 fusion gene.